Mikart Appoints Darrin Schellin Chief

Mikart announced a leadership change on July 7, 2026. Mikart appointed Darrin Schellin, most recently CEO of Pharma Tech Industries, to lead the CDMO’s next phase of growth as Michael Kallelis joined its Board of Directors.

What changed

Darrin Schellin was named Chief Executive Officer. As part of the transition, Michael Kallelis joined Mikart’s Board of Directors and will remain actively involved in supporting the company and providing strategic guidance to ensure continuity for clients, employees, and partners. The announcement does not name a predecessor CEO.

Leader: Darrin Schellin
Role: Chief Executive Officer
Effective: Not specified in the announcement
Announcement date: July 7, 2026

Leadership background

Schellin brings more than 20 years of executive leadership experience across the pharmaceutical, biotechnology, and CDMO sectors, the company said. He most recently served as Chief Executive Officer of Pharma Tech Industries and previously as Chief Executive Officer of GBI Bio. Earlier in his career, he held leadership roles with Alliance Medical Products and Siegfried.

The mandate

Mikart said Schellin will lead the company’s next phase of growth, with a focus on operational performance, customer partnerships, commercial expansion, and continued quality and service excellence.

Why this matters for GTM teams

Executive appointments can precede changes in strategy, operating cadence, hiring, partnerships, and technology priorities. The useful signal is not the title alone: teams should watch the new leader’s stated mandate, prior playbook, organizational scope, and the initiatives announced during the first two quarters.

Source and methodology

This leadership profile is based on the company’s announcement. Roles, transition timing, and biographical details are presented as announced; SalesTools Research does not infer undisclosed succession plans.

Mikart